Medication-related osteonecrosis of the jaw: An update.
Medication-related osteonecrosis of the jaw: An update.
复制标题
DOI：
10.4103/njms.njms_236_20
复制
发表时间：
2022-01
期刊：
影响因子：
--
通讯作者：
Bansal, Hitesh
中科院分区：
文献类型：
--
作者：
Bansal, Hitesh
抗吸收药物，如双膦酸盐和狄诺塞单抗，是一类重要的药物，用于治疗从骨质疏松症到多发性骨髓瘤的广泛疾病。不幸的是，它们也与一种罕见但毁灭性的副作用-药物相关的颌骨骨坏死（MRONJ）有关。2003年首次报道，该领域已经进行了大量研究;然而，确切的病理生理学仍然困扰着临床医生和研究人员。已经确定的是，静脉治疗、治疗时间和拔牙是主要的风险因素。已经提出了分期和治疗指南;然而，还没有普遍接受，临床医生依赖于各种立场文件。在接下来的30年里，老龄化人口将翻一番，与此同时，抗吸收药物的处方和MRONJ的发病率无疑将增加。2013年，Gupta等人发表了一篇关于双膦酸盐相关的颌骨骨坏死的论文;然而，自那时以来有许多变化。本文件旨在简要介绍这些变化的最新情况。
Antiresorptive medications, such as bisphosphonates and denosumab, are an important class of medication used to treat a wide range of diseases from osteoporosis to multiple myeloma. Unfortunately, they are also associated with a rare but devastating side effect – medication-related osteonecrosis of the jaw (MRONJ). First reported in 2003, much research has been done into the area; however, the exact pathophysiology continues to elude clinicians and researchers. What has been ascertained is that intravenous treatment, duration of treatment, and tooth extraction are major risk factors. Staging and treatment guidelines have been proposed; however, there has been no universal acceptance, and clinicians rely on various position papers. Over the next 30 years, the aging population is set to double, and with it, the prescription of antiresorptive medication and incidence of MRONJ will undoubtedly increase. In 2013, Gupta et al. published a paper on bisphosphonate-related osteonecrosis of the jaw; however, there have many changes since then. This paper aims to provide a succinct update on those changes.